Enzon Pharmaceuticals (OTCMKTS:ENZN) Share Price Crosses Above 200 Day Moving Average – Here’s What Happened

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZNGet Free Report)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.06 and traded as high as $0.0740. Enzon Pharmaceuticals shares last traded at $0.0740, with a volume of 655,000 shares changing hands.

Enzon Pharmaceuticals Stock Up 5.4%

The company has a market cap of $5.49 million, a P/E ratio of -1.48 and a beta of 0.20. The company has a 50 day moving average price of $0.05 and a 200-day moving average price of $0.06.

Enzon Pharmaceuticals (OTCMKTS:ENZNGet Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share for the quarter.

About Enzon Pharmaceuticals

(Get Free Report)

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.

Read More

Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.